What it's for (Indications)
- Lacosamide, marketed under various brand names including the example Lalap, is primarily indicated for the treatment of epilepsy.
- Specifically, it is approved as monotherapy and adjunctive therapy for the treatment of partial-onset seizures in patients 4 years of age and older.
- Additionally, lacosamide is approved for the adjunctive treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Its therapeutic efficacy stems from its ability to stabilize hyperexcitable neuronal membranes, reducing the frequency and severity of seizure activity.
- The decision to initiate lacosamide therapy should be made by a healthcare professional after careful consideration of the patient's seizure type, medical history, and potential for drug interactions, ensuring optimal patient outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of lacosamide (e.g., Lalap) must be individualized based on patient age, renal function, concomitant medications, and therapeutic response. For adults (17 years and older) with partial-onset seizures, monotherapy typically starts at 100 mg orally twice daily, or 50 mg twice daily and titrated up weekly by 50 mg increments to a target dose of 100 mg to 200 mg twice daily. Adjunctive therapy usually begins at 50 mg twice daily, with weekly increases of 50 mg increments to a maintenance dose of 100 mg to 200 mg twice daily. Pediatric dosing for partial-onset and primary generalized tonic-clonic seizures is weight-based and follows a similar titration schedule, often starting with lower doses and gradually increasing. Intravenous administration is also available for hospitalized patients when oral administration is temporarily not feasible, with similar dosing and titration strategies. Dosage adjustments are crucial in patients with mild to moderate renal impairment, and further reductions may be necessary in severe renal impairment or end-stage renal disease requiring hemodialysis. Abrupt discontinuation should be avoided due to the risk of increased seizure frequency or status epilepticus, necessitating gradual tapering. |
Safety & Warnings
Common Side Effects
- Lacosamide (e.
- g.
- , Lalap) is associated with a range of side effects, most commonly dose-dependent and affecting the central nervous system.
- Frequent adverse reactions reported by patients include dizziness, headache, nausea, diplopia (double vision), fatigue, ataxia (impaired coordination), blurred vision, tremor, and nystagmus (involuntary eye movement).
- Gastrointestinal disturbances such as vomiting and diarrhea may also occur.
- More serious, albeit less common, side effects warranting immediate medical attention include hypersensitivity reactions, which can manifest as skin rash, fever, and lymphadenopathy, potentially leading to Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome.
- Cardiac adverse effects, such as PR interval prolongation and dose-dependent bradycardia, have been observed, particularly in patients with pre-existing cardiac conditions or those on other medications affecting cardiac conduction.
- As with other antiepileptic drugs, there is an increased risk of suicidal thoughts or behavior.
- Patients should be closely monitored for new or worsening psychiatric symptoms, and prompt medical consultation is advised if such changes are noted.
Serious Warnings
- Black Box Warning: **Serious Warnings: Risk of Suicidal Thoughts and Behaviors** Lacosamide (e.g., Lalap), similar to other antiepileptic drugs (AEDs), does not carry a formal FDA Black Box Warning. However, it is crucial for healthcare professionals and patients to be aware of a serious and well-established safety concern: an increased risk of suicidal thoughts or behavior in patients taking AEDs for any indication. This warning applies to lacosamide, as clinical trials have shown a statistically significant increased risk of suicidality compared to placebo, aligning with the class effect observed across various AEDs. The exact mechanism by which AEDs increase this risk is not fully understood, but it is believed to be a multifactorial phenomenon involving alterations in neurotransmitter systems. Patients treated with any AED, including lacosamide, for any indication should be closely monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Such symptoms may manifest as agitation, irritability, aggression, panic attacks, insomnia, impulsivity, or new or worsening anxiety, and in rare cases, hypomania or mania. Families and caregivers of patients should be thoroughly informed about the need to monitor for these changes and to immediately report any concerning observations to a healthcare provider. Prescribers should carefully balance the potential risk of suicidality with the risk of untreated illness, which itself carries significant morbidity and mortality. If suicidal thoughts or behavior emerge during lacosamide treatment, the clinician must carefully re-evaluate the treatment plan, considering the potential need for dose adjustment, discontinuation of the medication, or initiation of alternative therapies. It is imperative that discontinuation of lacosamide be performed gradually to prevent the precipitation of withdrawal seizures or status epilepticus.
- Several critical warnings are associated with lacosamide (e.
- g.
- , Lalap) therapy.
- A significant concern is the increased risk of suicidal ideation and behavior, common to all antiepileptic drugs (AEDs).
- Patients and caregivers should be advised to monitor for changes in mood, behavior, or the emergence of suicidal thoughts and to seek medical attention immediately if such symptoms occur.
- Lacosamide can also prolong the PR interval and cause first-degree atrioventricular (AV) block, which may lead to syncope or, rarely, more serious cardiac arrhythmias, especially in patients with pre-existing cardiac conduction problems or those taking other drugs that prolong the PR interval.
- Dizziness and ataxia are common, dose-related adverse events that can increase the risk of accidental injury, such as falls.
- Patients should be cautioned about engaging in activities requiring mental alertness, such as driving or operating heavy machinery, until they know how the drug affects them.
- Severe cutaneous adverse reactions, including DRESS syndrome, have been reported and require immediate discontinuation of the medication.
- Abrupt withdrawal of lacosamide may precipitate an increase in seizure frequency or status epilepticus, necessitating gradual dose reduction when discontinuing the drug.
How it Works (Mechanism of Action)
Lacosamide (e.g., Lalap) exerts its anticonvulsant effects primarily through the selective enhancement of slow inactivation of voltage-gated sodium channels. Unlike conventional sodium channel blockers that primarily affect fast inactivation, lacosamide's unique mechanism modulates sodium channel activity by enhancing the slow inactivation phase. This action stabilizes hyperexcitable neuronal membranes and inhibits repetitive neuronal firing, thereby reducing the propagation of seizure activity in the brain. The drug's affinity for this mechanism is voltage-dependent, meaning it preferentially binds to and modulates sodium channels that are in an inactivated state, which is characteristic of neurons involved in seizure generation. This selective action contributes to its therapeutic efficacy in treating focal-onset and primary generalized tonic-clonic seizures, differentiating it from other AEDs. Additionally, lacosamide is known to bind to the collapsin response mediator protein 2 (CRMP2), though the precise contribution of this interaction to its overall antiepileptic effect is still under investigation.